LACTERA THERAPEUTICS, INC.  ·  U.S. DELAWARE C-CORPORATION  ·  WOUND HEALING & REGENERATIVE SCIENCE
Bioactive Wound Healing & Tissue Regeneration Platform

Transforming Wound Healing Through Science

LACTERA Therapeutics, Inc. is a U.S. biotechnology company advancing science-driven, cell-free bioactive solutions for wound healing, tissue repair, and regenerative healthcare. Built upon proprietary fermentation technology, peer-reviewed clinical trials, and real-world validation, LACTERA bridges scientific innovation with clinical practice to improve outcomes for patients with acute and chronic wounds.

94%
Complete Healing at 24 Weeks
vs. 64% in control group (P = 0.003; BJD 2026 Double-Blind RCT)
11 Days
STSG Donor Site Closure
Reduced from 17 days in control cohort (JWC / WUWHS 2026)
0%
Clinical Adverse Events
Longitudinal safety evaluation across clinical cases (SCMJ 2025)
2°C–40°C
Cold-Chain-Free Stability
36-month ambient structural integrity without refrigeration

Key Highlights

  • U.S. Delaware C-Corporation
  • Proprietary Cell-Free Bioactive Ferment Filtrate Platform
  • Patent-Protected Technology & Undisclosed Process Trade Secrets
  • Peer-Reviewed Multi-Center Clinical Trials & Real-World Evidence
  • Validated International Clinical & Humanitarian Deployment
  • Asset-Light Global Research & Licensing Strategy

Focus Areas & Global Vision

To establish a globally recognized biotechnology platform delivering innovative, evidence-based wound care and regenerative solutions that improve patient recovery worldwide.

Advanced Wound Care Skin Barrier Recovery Tissue Regeneration Regenerative Medicine Translational Innovation

Improvement, Not Setback.

Across the globe, millions of patients suffering from diabetic foot ulcers, chronic non-healing wounds, post-surgical defects, and complex burns face prolonged recovery cycles, antimicrobial resistance, and limited access to cold-chain-dependent biologics.

Why We Exist

LACTERA Therapeutics, Inc. was founded to address critical unmet clinical needs in complex wound care—where conventional passive dressings fail to resolve stalled healing, and antimicrobial agents risk cytotoxicity or resistance.

By integrating microecological modulation with plant-derived extracellular matrix (ECM) simulation, our platform supports natural tissue repair without live bacteria, antibiotics, heavy-metal ions, or cold-chain infrastructure.

Corporate Structure & Core Values

Organized as a U.S. Delaware C-Corporation, LACTERA serves as the central platform for global intellectual property stewardship, international clinical research collaboration, and strategic commercialization.

  • Scientific Excellence: Rigorous analytical and clinical validation
  • Patient-Centered Innovation: Accessible, non-invasive care
  • Clinical Integrity: Transparent, peer-reviewed evidence
  • Global Collaboration: Cross-border clinical and institutional partnerships

Cell-Free Bioactive Ferment Filtrate System

Developed through multi-strain anaerobic co-culture fermentation (Bifidobacterium and Lactobacillus species with plant-based soybean substrate), LACTERA’s cell-free filtrate functions via dual physical and microenvironmental mechanisms.

1. Bioactive Microecological Barrier

Enriched with natural organic acids (pH 3.3–3.6), the fluidic barrier maintains a physiological mildly acidic wound microenvironment and creates a physical impediment to bacterial quorum-sensing and biofilm colonization without heavy-metal cytotoxicity.

2. Plant-Based ECM Simulation

100% plant-derived soybean matrix eliminates zoonotic cross-infection risks. Low-molecular-weight bioactive peptides (<1 kDa) and plant-derived extracellular vesicles structurally mimic human ECM to support fibroblast migration and orderly re-epithelialization.

3. Field-Ready Clinical Logistics

Calibrated 360° mist delivery (0.14 mL/spray) conforms uniformly to deep, irregular wound beds. Ambient stability across 2°C–40°C for 36 months eliminates cold-chain requirements and integrates into standard care protocols in 60 seconds.

Target Clinical Research Applications

Acute Traumatic Wounds Chronic Non-Healing Wounds Diabetic Foot Ulcers (DFU) Split-Thickness Skin Graft (STSG) Donor Sites Post-Surgical Wound Management Complex Thermal & Soft-Tissue Recovery

Analytical Rigor & International Academic Recognition

Our scientific framework is anchored in quantitative analytical sequencing (LC-MS, LC-UV, NanoFCM), standardized international nomenclature, and peer-reviewed clinical investigation presented at leading global wound healing forums, including the World Union of Wound Healing Societies (WUWHS 2026 Congress).

11,300 PPM
Natural Organic Acids
Maintains physiological pH 3.3–3.6 microenvironmental barrier
4,900 PPM
Low-MW Peptides
92 sequenced chains via LC-MS; 75% < 1 kDa for rapid bioavailability
1.1 × 1010
Plant Exosomes / mL
NanoFCM confirmed EVs (92–97 nm) supporting tissue regeneration
45,400 U
SOD-Like Activity / 100mL
Antioxidant defense against oxidative stress in wound beds
1,030 PPM
Free Amino Acids & 575 PPM Nucleotides
Essential cellular building blocks for epidermal recovery

Peer-Reviewed Clinical Trials & Safety Profile

The safety and clinical performance of the LACTERA® bioactive dressing system have been evaluated across prospective randomized controlled trials, multi-center cohort studies, and longitudinal safety assessments.

Chronic Wounds Double-Blind RCT

British Journal of Dermatology (2026)
ClinicalTrials.gov: NCT07008573

Achieved 94% complete wound healing at 24 weeks vs. 64% in control (P = 0.003), reducing mean time to full closure from 165.9 days to 89.6 days (P = 0.012).

STSG Donor Site Management

Journal of Wound Care (2026) & WUWHS 2026

Significantly reduced mean donor site healing time from 17 days down to 11 days (~35% reduction), lowering dressing change frequency and patient discomfort.

Diabetic Foot Ulcers & Safety

JWC (2023) & SCMJ (2025)

Achieved 83% complete healing within 16 weeks in DFU cohorts with PAOD/ESRD (mean 51 days), with 0% clinical adverse events across longitudinal safety tracking.

Table 1 Summary of all results of wound healing outcomes by treatment group; no further amputations or mortalities were observed in this study
Outcome Bottle A
(n = 36)
Bottle B
(n = 22)
P-value
Complete healing by 24 weeks, n (%) 34 (94) 14 (64) 0.003
Mean days to full healing, mean (SD) 89.6 (17.6) 165.9 (68.3) 0.012
Wound area reduction, mean (SD), days
25% reduction 22.4 (5.46) 30.8 (14.00) 0.032
50% reduction 29.4 (7.35) 49.7 (23.17) 0.028
75% reduction 49.0 (12.25) 84.0 (31.14) 0.021
100% reduction 89.6 (17.64) 165.9 (68.25) 0.012
Healing at specific timepoints, n (%)
4 weeks 6 (17) 3 (14) 0.757
8 weeks 15 (42) 7 (32) 0.453
12 weeks 21 (58) 8 (36) 0.104
16 weeks 25 (69) 9 (41) 0.032
20 weeks 33 (92) 10 (45) < 0.001
24 weeks 34 (94) 14 (64) 0.003
P-values < 0.05 were considered statistically significant.
Source: Hsu H, Yang CC, et al. British Journal of Dermatology (BJD), 2026; 194(6):1192–1194 (ClinicalTrials.gov: NCT07008573). Bottle A: Active LACTERA® group; Bottle B: Control group.

Peer-Reviewed Academic References

  1. Hsu H, Yang CC, Huang SM, Wu MS, Yao HE, Lin YW. Topical probiotics in soybean concentrate for diabetic foot ulcers: a randomized controlled trial. British Journal of Dermatology (BJD), 2026, Vol. 194, No. 6, pp. 1192–1194.
  2. Yang CC, Wu SH, Wu MS, Cheng YT, Yao HE, Lin YW, Hsu H. Clinical Comparative Study of Topical Probiotics in Soybean Concentrate in the Management of Split-Thickness Skin Graft Donor Sites. Journal of Wound Care (JWC), 2026, [Epub ahead of print]. Featured presentation at WUWHS 2026 Congress.
  3. Yang CC, Wu MS, Hsu H. Management of diabetic foot ulcers using topical probiotics in a soybean-based concentrate: a multicenter study. Journal of Wound Care (JWC), 2023, Vol. 32, No. 12 (Suppl 12), pp. S16–S23.
  4. Huang TY, Chiang TW, Fu HK, Chen CF, Tseng SY, Lee TH. Macroscopic evaluation of clinical application and efficacy of aqueous wound dressing containing probiotic components. Show-Chwan Medical Journal, 2025, Vol. 24, No. 2, pp. 284–288.

Multi-Layered IP & Proprietary Trade Secret Protection

LACTERA Therapeutics maintains a disciplined intellectual property architecture designed to safeguard core biological manufacturing processes against reverse engineering while establishing durable commercial barriers.

Undisclosed Formulations & Trade Secrets

To protect proprietary process advantages, our multi-strain anaerobic co-culture parameters, microbial acclimation protocols, exact compositional ratios, and cell-free extraction methods are strictly maintained as confidential trade secrets and undisclosed proprietary know-how.

Granted Patent & Standardized Nomenclature

  • Granted Invention Patent: Compositional wound-healing patent protection valid through 2039.
  • Official INCI Registration: Registered with the Personal Care Products Council (PCPC, Application No. 2018-7484) as Bifidobacterium / Lactobacillus / Soybean / Sucrose Ferment Filtrate (Trade Name: LACTERA®).
  • Proprietary Data Assets: Exclusive ownership of clinical trial datasets and analytical characterization matrices.

Confidentiality & Licensing Framework

Detailed formulation specifications, manufacturing know-how, and technical dossiers are disclosed exclusively to qualified institutional investors, research institutions, and strategic partners upon execution of a standard Mutual Non-Disclosure Agreement (Mutual NDA).

Real-World Clinical Validation & International Expansion

LACTERA combines established real-world healthcare utilization with an asset-light international expansion model built around clinical partnerships, local sterile filling collaborations, and technology licensing.

International Clinical & Humanitarian Deployment

LACTERA Therapeutics has successfully completed its initial product donation and clinical deployment to the National Rehabilitation Center "Unbroken" in Ukraine, receiving highly positive feedback from frontline medical teams regarding ease of application and wound management performance.

United States

Corporate headquarters (Delaware C-Corporation), global IP governance, scientific affairs coordination, and institutional investor relations.

Europe & Ukraine

Ongoing complex wound care clinical collaboration and asset-light local sterile filling & regulatory partnerships (ISO 13485 partner model).

Asia-Pacific Markets

Established commercial utilization and real-world clinical experience supporting ongoing product validation and international expansion.

Multidisciplinary Team Bridging Science & Commercialization

LACTERA Therapeutics is guided by an international team integrating corporate strategy, peer-reviewed clinical research, and cross-border healthcare operations.

Executive Leadership & Strategy

Leads corporate governance, global intellectual property strategy, institutional partnerships, and capital allocation under a U.S. Delaware C-Corporation structure, focusing on scalable international commercialization pathways.

Scientific Advisory Board

Comprises principal investigators and clinical specialists in dermatology, reconstructive surgery, and complex wound care who have authored peer-reviewed studies in BJD and JWC and presented at the WUWHS Congress.

Clinical & Technical Operations

Oversees formulation standardization, ambient stability validation (2°C–40°C), quality compliance, and clinical deployment across healthcare centers and international medical networks.

* Detailed executive biographies, curriculum vitae, and principal investigator credentials are available to qualified institutional investors and clinical partners upon request under a Mutual NDA.

Partnering to Advance Global Wound Care

LACTERA welcomes dialogue with institutional healthcare investors, biotechnology venture funds, family offices, corporate venture groups, and international clinical or licensing partners.

Investment Highlights

  • Protected intellectual property & undisclosed fermentation trade secrets
  • Peer-reviewed double-blind RCT evidence (BJD & JWC)
  • Cold-chain-free logistics advantage (2°C–40°C for 36 months)
  • Asset-light international licensing & local sterile filling scalability

Strategic Use of Capital

  • International clinical research expansion & multi-center registries
  • Global regulatory pathway advancement & dossier preparation
  • Intellectual property portfolio expansion & trade secret protection
  • International commercial partnerships & market development

Connect With LACTERA Therapeutics

For investor materials, research collaboration proposals, or licensing inquiries under Mutual NDA, please contact our executive office directly.